RT Journal Article
T1 From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer
A1 Chang, Hang
A1 Yang, Xu
A1 Moore, Jade
A1 Liu, Xiao Ping
A1 Jen, Kuang Yu
A1 Snijders, Antoine M.
A1 Ma, Lin
A1 Chou, William
A1 Corchado Cobos, Roberto
A1 García Sancha, Natalia
A1 Mendiburu-Eliçabe Garganta, Marina
A1 Pérez Losada, Jesús
A1 Barcellos Hoff, Mary Helen
A1 Mao, Jian Hua
AB Mouse models of cancer provide a powerful tool for investigating all aspects of cancer biology. In this study, we used our recently developed machine learning approach to identify the cellular morphometric biomarkers (CMB) from digital images of hematoxylin and eosin (H&E) micrographs of orthotopic Trp53-null mammary tumors (n = 154) and to discover the corresponding cellular morphometric subtypes (CMS). Of the two CMS identified, CMS-2 was significantly associated with shorter survival (p = 0.0084). We then evaluated the learned CMB and corresponding CMS model in MMTV-Erbb2 transgenic mouse mammary tumors (n = 53) in which CMS-2 was significantly correlated with the presence of metastasis (p = 0.004). We next evaluated the mouse CMB and CMS model on The Cancer Genome Atlas breast cancer (TCGA-BRCA) cohort (n = 1017). Kaplan–Meier analysis showed significantly shorter overall survival (OS) of CMS-2 patients compared to CMS-1 patients (p = 0.024) and added significant prognostic value in multi-variable analysis of clinical and molecular factors, namely, age, pathological stage, and PAM50 molecular subtype. Thus, application of CMS to digital images of routine workflow H&E preparations can provide unbiased biological stratification to inform patient care.
SN 2234-943X
YR 2022
FD 2022
LK https://hdl.handle.net/20.500.14352/100438
UL https://hdl.handle.net/20.500.14352/100438
LA eng
NO Chang H, Yang X, Moore J, Liu X-P, Jen K-Y, Snijders AM, et al. From Mouse to Human: Cellular Morphometric Subtype Learned From Mouse Mammary Tumors Provides Prognostic Value in Human Breast Cancer. Front Oncol 2022;11:819565. https://doi.org/10.3389/fonc.2021.819565.
NO Department of Defense (Estados Unidos)
NO National Cancer Institute (Estados Unidos)
NO National Institutes of Health (Estados Unidos)
NO University of California (Estados Unidos)
DS Docta Complutense
RD 20 dic 2025